Results 171 to 180 of about 41,075 (183)

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Lancet, The, 2021
Victoria R Cornelius, Katrina Cathie, Yvanne Enever   +2 more
exaly  

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

New England Journal of Medicine, 2021
Stephen J Thomas, Edson Duarte Moreira, Judith Absalon   +2 more
exaly  

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

New England Journal of Medicine, 2021
Laith Abu-Raddad, Hiam Chemaitelly, Adeel A Butt   +2 more
exaly  

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

New England Journal of Medicine, 2021
Yinon M Bar-On, Yair Goldberg, Micha Mandel   +2 more
exaly  

Neutralizing Activity of BNT162b2-Elicited Serum

New England Journal of Medicine, 2021
Jianying Liu, Hongjie Xia, Camila R Fontes-Garfias   +2 more
exaly  

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

New England Journal of Medicine, 2021
Robert W Frenck, Judith Absalon, Alejandra Gurtman   +2 more
exaly  

Waning Immunity after the BNT162b2 Vaccine in Israel

New England Journal of Medicine, 2021
Yair Goldberg, Micha Mandel, Yinon M Bar-On   +2 more
exaly  

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine

New England Journal of Medicine, 2022
Edson Duarte Moreira, Stephen Lockhart, Alejandra Gurtman   +2 more
exaly  

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

New England Journal of Medicine, 2021
Dror Mevorach, Michal, Tal Hasin
exaly  

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

New England Journal of Medicine, 2021
Noa Dagan, Noam Barda, Eldad Kepten
exaly